title: Use of various offset settings in the Fenwal Amicus during hematopoietic progenitor cell collection to increase lymphocyte yield and reduce cross-cellular contamination.
abstract: BACKGROUND
  Autologous HPC collection focus has been CD34+ cell yield but product content of other cells is important for patient survival, complications, and resource utilization.
  
  
  METHODS
  Prospective, paired study examining MNC and RBC offsets (opens and closes collect valve, respectively) was performed using Fenwal Amicus. Lymphocyte, CD34+ cell yields, and cross-cellular contamination were compared using different MNC/RBC offsets and retrospective Spectra data.
  
  
  RESULTS
  In paired comparisons, median lymphocyte yields were significantly different only between 0.0/7.0 (17.6 × 10(9)) and 1.5/5.0 (14.5 × 10(9)) offsets. CD34+ yields were not significantly different between offsets except 1.0/7.0 and 1.5/5.0 (230.3 vs. 156.7 × 10(6)). Granulocytes, RBC, and PLT were significantly greater with higher RBC offset. Comparing all offsets, 1.5/5.0 collected fewer lymphocytes, granulocytes, RBC, and PLT. 1.5/6.0 offsets collected more lymphocytes than 1.5/5.0 but fewer granulocytes and RBC than others except 1.5/5.0. For 1.5/6.0 offsets, PLT content was higher than 1.5/5.0, equivalent to the other offsets, and less than Spectra. CD34+ yields for 1.5/6.0 offsets were equivalent to others except 1.0/7.0. Manufacturer's default (2.3/6.8) collected equivalent lymphocytes and CD34+ to all offsets (except 1.0/7.0) and Spectra. Cross-cellular contamination was higher than 1.5/5.0 and 1.5/6.0 but equivalent to others with more RBC and fewer PLT than Spectra.
  
  
  CONCLUSIONS
  For maximum lymphocyte yield and minimum contamination, 1.5/6.0 offsets appear optimal. For minimum lymphocyte yield and contamination, 1.5/5.0 offsets would be preferred. Manufacturer's default has CD34+ cell and lymphocyte yields similar to 1.5/6.0 with greater contamination. Amicus can achieve lymphocyte and CD34+ yields similar to Spectra but has significantly less PLT removal.
authors.affiliation: Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Edwin A
authors.initials: EA
authors.lastname: Burgstaler
authors.forename: Luis F
authors.initials: LF
authors.lastname: Porrata
authors.forename: Svetomir N
authors.initials: SN
authors.lastname: Markovic
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Winters
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D001781:Blood Component Removal / Q000295:instrumentation* / Q000379:methods; D002469:Cell Separation / Q000295:instrumentation* / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D008214:Lymphocytes / Q000166:cytology*
chemical_list: D018952:Antigens, CD34